SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Nicholson Andrew G.)
 

Search: WFRF:(Nicholson Andrew G.) > PD-L1 Testing for L...

  • Lantuejoul, SylvieCtr Leon Berard Unicanc, Lyon, France.;Univ Grenoble Alpes, Grenoble, France. (author)

PD-L1 Testing for Lung Cancer in 2019 : Perspective From the IASLC Pathology Committee

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • Elsevier BV,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-409968
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409968URI
  • https://doi.org/10.1016/j.jtho.2019.12.107DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (ICs) by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms, and many laboratories have set up in-house or laboratory-developed tests that are more affordable than the generally expensive clinical trial-validated assays. Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. Because many articles have been published since the issue of the IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, this review by the IASLC Pathology Committee provides updates on the indications of ICIs for lung cancer in 2019 and discusses important considerations on preanalytical, analytical, and postanalytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance, and training.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sound-Tsao, MingUniv Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. (author)
  • Cooper, Wendy A.Royal Prince Alfred Hosp, Camperdown, NSW, Australia. (author)
  • Girard, NicolasInst Curie, Paris, France.;Univ Claude Bernard, Lyon, France. (author)
  • Hirsch, Fred R.Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA.;Mt Sinai Hlth Syst, Ichan Sch Med, New York, NY USA. (author)
  • Roden, Anja C.Mayo Clin, Rochester, MN USA. (author)
  • Lopez-Rios, FernandoHM Hosp, Pathol Lab Dianas Terapeut, Madrid, Spain. (author)
  • Jain, DeepaliAll India Inst Med Sci, New Delhi, India. (author)
  • Chou, Teh-YingTaipei Vet Gen Hosp, Taipei, Taiwan. (author)
  • Motoi, NorikoNatl Canc Ctr, Tokyo, Japan. (author)
  • Kerr, Keith M.Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland. (author)
  • Yatabe, Yasushi (author)
  • Brambilla, ElisabethUniv Grenoble Alpes, Grenoble, France. (author)
  • Longshore, JohnCarolinas Pathol Grp, Charlotte, NC USA. (author)
  • Papotti, MauroUniv Turin, Turin, Italy. (author)
  • Sholl, Lynette M.Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA. (author)
  • Thunnissen, ErikVrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands. (author)
  • Rekhtman, NatashaMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. (author)
  • Borczuk, AlainWeill Cornell Med, New York, NY USA. (author)
  • Bubendorf, LukasUniv Basel, Inst Pathol, Basel, Switzerland. (author)
  • Minami, YukoIbarakihigashi Natl Hosp, Tokai, Ibaraki, Japan. (author)
  • Beasley, Mary BethMt Sinai Hlth Syst, Ichan Sch Med, New York, NY USA. (author)
  • Botling, JohanUppsala universitet,Klinisk och experimentell patologi,Uppsala Univ Hosp, Uppsala, Sweden,Johan Botling(Swepub:uu)johanbot (author)
  • Chen, GangFudan Univ, Zhongshan Hosp, Shanghai, Peoples R China. (author)
  • Chung, Jin-HaengSeoul Natl Univ, Bundang Hosp, Seoul, South Korea. (author)
  • Dacic, SanjaUniv Pittsburgh, Med Ctr, Pittsburgh, PA USA. (author)
  • Hwang, DavidSunnybrook Hlth Sci Ctr, Toronto, ON, Canada. (author)
  • Lin, DongmeiPeking Univ, Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China. (author)
  • Moreira, AndreNYU, Sch Med, New York, NY USA. (author)
  • Nicholson, Andrew G.Royal Brompton & Harefield NHS Fdn Trust, London, England.;Imperial Coll, Natl Heart & Lung Inst, London, England. (author)
  • Noguchi, MasayukiUniv Tsukuba, Tsukuba, Ibaraki, Japan. (author)
  • Pelosi, GiuseppeUniv Milan, Milan, Italy.;IRCCS MultiMed, Milan, Italy. (author)
  • Poleri, ClaudiaOff Pathol Consultants, Buenos Aires, DF, Argentina. (author)
  • Travis, WilliamMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. (author)
  • Yoshida, AkihikoNatl Canc Ctr, Tokyo, Japan. (author)
  • Daigneault, Jillian B.Int Assoc Study Lung Canc, Aurora, CO USA. (author)
  • Wistuba, Ignacio I.Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. (author)
  • Mino-Kenudson, MariMassachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 122, Boston, MA 02114 USA. (author)
  • Ctr Leon Berard Unicanc, Lyon, France.;Univ Grenoble Alpes, Grenoble, France.Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. (creator_code:org_t)

Related titles

  • In:Journal of Thoracic Oncology: Elsevier BV15:4, s. 499-5191556-08641556-1380

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view